Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

about

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Item

http://www.wikidata.org/entity/Q48573554

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@en

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@nl

type

Item

label

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@en

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@nl

prefLabel

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@en

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@nl

P1476

Fludarabine and Busulfan versu ...... tation in Follicular Lymphoma.

@en

P2093

Anna Sureda

http://www.w3.org/2001/XMLSchema#string

Bipin Savani

http://www.w3.org/2001/XMLSchema#string

Kwang Woo Ahn

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Mehdi Hamadani

http://www.w3.org/2001/XMLSchema#string

Narendranath Epperla

http://www.w3.org/2001/XMLSchema#string

Nirav N Shah

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Sairah Ahmed

http://www.w3.org/2001/XMLSchema#string

Samantha Jaglowski

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

Defining the intensity of conditioning regimens: working definitions

B cells in chronic graft-versus-host disease

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

P304

78-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2017.10.011

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29032272

http://www.w3.org/2001/XMLSchema#string

P932

5743624

http://www.w3.org/2001/XMLSchema#string